March 2, 2017 / 9:29 PM / in 8 months

BRIEF-Otonomy qtrly loss per share $0.88

March 2 (Reuters) - Otonomy Inc:

* Otonomy Inc qtrly loss per share $0.88

* Says topline data for oto-104 phase 3 trials expected in 2H2017

* Otonomy Inc - realigned sales territories to optimize coverage of accounts with current or near-term potential for otiprio utilization

* Says realignment enabled co to reduce size of sales force from 40 to 20 sales representatives

* Says in addition, Otonomy’s chief commercial officer has left company

* Expects submission of an SNDA to FDA for otiprio in AOE in the first half of 2017 Source text: (bit.ly/2mLfngn) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below